Effects of Nicotinamide Riboside on Metabolism and Vascular Function

Not Applicable

Completed

• Conditions: Lipemia; Aging
• Interventions: Dietary Supplement: Nicotinamide riboside chloride (Niagen); Dietary Supplement: Placebo

• Registration Number: NCT03501433
• Lead Sponsor: Iowa State University

Brief Summary

The purpose of this study is to determine the effects of Nicotinamide Riboside (NR) supplementation on metabolism and vascular function following high-fat meal. Differences between young (18-35) and older (60-75) adults will be determined.

Detailed Description

The purpose of this study is to determine the effects of 7 days of Nicotinamide Riboside (NR) or placebo supplementation on metabolism and vascular function following high-fat meal. Differences between young (18-35) and older (60-75) adults will be determined.

Study Timeline

• Study Start: 2018-02-01
• Study First Submitted: 2018-04-10
• Study First Submitted QC: 2018-04-10
• Study First Posted: 2018-04-18
• Primary Completion: 2019-12-01
• Study Completion: 2019-12-01
• Status Verified: 2020-09
• Last Update Submitted: 2020-09-23
• Last Update Posted: 2020-09-25

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 16

Inclusion Criteria

• Age 18 to 35 (young) and 60 to 75 (older)
• Normo- or pre-hypertensive (blood pressure <140/90 mmHg)
• Non-smokers
• Able to give informed consent and participate in all laboratory visits

Exclusion Criteria

• Currently taking any medications that could interfere with cardiovascular or metabolic outcomes will be excluded from the study (e.g., beta-blockers)
• Known metabolic (e.g. Type I or Type II diabetes, cardiovascular disease, etc.) or immunologic (e.g. HIV, cancer, autoimmune, etc.) diseases
• Food allergies to egg, milk, soy or wheat
• Women who are pregnant or planning to become pregnant during the course of the study,
• Pacemaker or other implanted device
• Unwilling to participate in the experimental protocol or blood draws will be excluded

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: CROSSOVER

Arm && Interventions

Group	Intervention	Description
Nicotinamide Riboside Chloride (Niagen)	Nicotinamide riboside chloride (Niagen)	7 days of nicotinamide riboside supplementation (250 mg/d x 2/day).
Placebo	Placebo	7 days of placebo supplementation (2/day)

Primary Outcome Measures

Name	Time	Method
NAD+	7 days	Blood and peripheral blood mononuclear cell (PBMC) levels

Secondary Outcome Measures

Name	Time	Method
Lipdemia	7 days	Fasting and postprandial
Vasodilatory responsiveness	7 days	Post-Occlusion Reactive Hyperemia (PORH)
Oxidative stress and inflammation	7 days	Plasma markers and expression in circulating PBMCs

Trial Locations

Locations (1)

Iowa State University; 🇺🇸 Ames, Iowa, United States